Lipid-lowering for peripheral arterial disease of the lower limb

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Aung, Phyu Phyu ^a   Maxwell, H G ^b   Jepson, R G ^b   Price, J F ^b   Leng, G C ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NONE

Author keywords

Antilipemic agents *therapeutic use ; Arteriosclerosis *drug therapy ; Female; Humans; Leg *blood supply ; Male; Peripheral vascular diseases *drug therapy ; Randomized controlled trials as topic

Indexed keywords

ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; ATORVASTATIN; BETAPYRIDYL CARBINOL; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLICOSANOL; PROBUCOL; SIMVASTATIN; SULODEXIDE;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ASTHENIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; GAIT; GASTROINTESTINAL SYMPTOM; GRANULOMA; HEARTBURN; HUMAN; INJECTION SITE PAIN; LEG ARTERY; LEG DISEASE; LIPID BLOOD LEVEL; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MUSCLE CRAMP; MYALGIA; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 44949206501     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000123.pub2     Document Type: Review

References (124)

1. Bonalumi 1986 {published data only} Bonalumi F, Sarcina A, Bonadeo P, Maddinelli L. A randomized protocol for the management of chronic peripheral arterial diseases by means of sulodexide. European Review for Medical & Pharmacological Sciences 1986;8(2):123-9.
2. Caramelli 1988 {published data only} Caramelli L, Mirchioni R, Carini A. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations. European Review for Medical Pharmacological Sciences 1988;10 (1):55-8.
3. Castano 1999 {published data only} Castano G, Mas R, Roca J, Fernandez L, Illnait J, Fernandez JC, et al.A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999; 50(2):123-30.
4. Castano 2001 {published data only} Castano G, Mas Ferreiro R, Fernandez L, Gamez R, Illnait J, Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52(2):115-25.
5. Castano 2003 {published data only} Castano G, Mas R, Fernandez L, Gamez R, Illnait J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003;54(1):25-38.
6. Coccheri 2002 {published data only} Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. European Heart Journal 2002;23(13):1057- 65.
7. Corsi 1985 {published data only} Corsi C, Bocci L, Cipriani C, Gazzini A, Marrapodi E. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial. Journal of International Medical Research 1985;13(1):40-7.
8. Cospite 1985 {published data only} Cospite M, Milio G, Ferrara F. Double-blind study of the pharmacological effects of sulodexide in patients with multiple atherosclerotic vascular disease. European Review for Medical & Pharmacological Sciences 1985;7(1):97-106.
9. Gans 1990 {published data only} Gans RO, Bilo HJ, Weersink EGL, Rauwerda JA, Fonk T, Popp-Snijders C, et al.Fish oil supplementation in patients with stable claudication. American Journal of Surgery 1990;160(5):490-5.
10. HPS {published data only} Anonymous. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. European Heart Journal 1999;20 (10):725-41.
11. Collins R. The MRC/BHF heart protection study. HPS INFORMATION. www.ctsuox.ac.uk 2001 (accessed 13 October 2004).
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16.
13. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363(9411):757- 67.
14. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. International Journal of Clinical Practice 2002;56(1):53-6.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. [see comments.]. Lancet 2002;360(9326):23-33.
16. *Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. [see comments.]. Lancet 2002;360(9326):7-22.
17. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery 2007;45(4):645-54.
18. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. BMC Medicine 2005;3:6.
19. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Heart Protection Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.[see comment]. Lancet 2005;365(9473): 1779-85.
20. LEADER {published data only} Hogg CF, Zuhrie SR, Meade TW. Trial of bezafibrate in lower extremity arterial disease pilot study results. Thrombosis & Haemostasis 1995;73(6):1328-Abstract No 1645.
21. Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 2002;163(1):183-92.
22. *Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325(7373):1139-41.
23. Meade TW. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):195-204.
24. MRC Epidemiology and Medical Care Unit, MRC General Practice Research Framework. Lower extremity arterial disease event reduction. Trial of bezafibrate in lower extremity arterial disease. Unpublished work 1996.
25. Liguori 1993 {published data only} Liguori L, Saviano M, Lampugnani R, Spartera C, Bonavita E, Frasson P, et al.Efficacy, tolerability, and dose-effect relationship of oral sulodexide in obstructive peripheral arterial disorders. Advances in Therapy 1993;10(2):52-66.
26. Mohler 2003 {published data only} Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108(12):1481-6.
27. Mondillo 2003 {published data only} Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al.Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. American Journal of Medicine 2003;114 (5):359-64.
28. Nye 1973 {published data only} Nye ER, Macbeth WA. The treatment of intermittent claudication with betapyridyl carbinol over two years. Atherosclerosis 1973;17(1): 95-106.
29. Palmieri 1984 {published data only} Palmieri G, Nazzari M, Ambrosi G, et al.Sulodexide in the treatment of peripheral arterial disease. Clinical Trials Journal 1984;21(6):411-27.
30. PQRST {published data only} Erikson U, Nilsson S, Stenport G. Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. American Journal of Cardiology 1988;62 (3):44B-47B.
31. Holme I, Malmaeus I, Olsson AG, Nilsson S, Walldius G. Repeated measurements over time: statistical analysis of the angiographic outcomes in the Probucol Quantitative Regression Swedish Trial (PQRST). Clinical Trials & Meta-Analysis 1993;28(2):95-108.
32. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, et al.Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish trial (PQRST) Report. Arteriosclerosis, Thrombosis & Vascular Biology 1995;15(8):1049-56.
33. Regnstrom J, Walldius G, Nilsson S, Elinder LS, Johansson J, Molgaard J, et al.The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996;125(2):217-29.
34. Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Molgaard J, et al.Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regession Trial (PQRST): a status report. American Journal of Cardiology 1988;62(3):37B-43B.
35. *Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, et al.The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). American Journal of Cardiology 1994;74(9):875-83.
36. Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, et al.The role of lipids and antioxidative factors for the developement of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). American Journal of Cardiology 1993; 71(6):15B-19B.
37. St Thomas' Trial {published and unpublished data} *Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983;2(8351):639-42.
38. Duffield RG, Miller NE, Jamieson CW, Lewis B. A controlled trial of plasma lipid reduction in peripheral atherosclerosis - an interim report. British Journal of Surgery 1982;69(Suppl):S3-5.
39. Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Medica Scandinavica Supplementum 1985;701:53-57.
40. ADMIT Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, et al.Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal 2000;140(4):631-6.
41. *Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, et al.Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology 1999;83 (4):569-75.
42. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al.Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284(10):1263-70.
43. Garg R, Elam MB, Crouse JR 3rd, Davis KB, Kennedy JW, Egan D, et al.Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal 2000;140(5):792-803.
44. Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal 1999;138(6 Pt 1):1082-7.
45. Pettinger MB, Waclawiw MA, Davis KB, Thomason T, Garg R, Griffin B, et al.Compliance to multiple interventions in a high risk population. Annals of Epidemiology 1999;9(7):408-18.
46. Philipp CS, Cisar LA, Saidi P, Kostis JB. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. American Journal of Cardiology 1998;82(5):697-9.
47. Aguilera 2004 Aguilera CM, Mesa MD, Ramirez-Tortosa MC, Nestares MT, Ros E, Gil A. Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. Clinical Nutrition 2004;23(4):673-681. [MEDLINE: 6271].
48. Altmann 1986 Altmann E, Schmidt PKH, Nowak R, Hotzel M. Results of a clinical double blind study about the efficacy of pentoxifyllin (POF) for patients with peripheral arterial perfusional disturbances in the state II according to Fontaine. Zeitschrift fur Klinische Medizin 1986;41 (9):667-70. [MEDLINE: 5876].
49. Aronow 2003 Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. American Journal of Cardiology 2003;92(6):711-2.
50. Attanasio 2001 Attanasio E, Russo P, Allen SE. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clinical Therapeutics 2001; 23(2):276-83.
51. Bartolo 1984 Bartolo M, Antignani PL, Eleuteri P. Experiences with sulodexide in the arterial peripheral diseases. Current Therapeutic Research, Clinical & Experimental 1984;36(51):979-88.
52. Berrettini 1996 Berrettini M, Parise P, Ricotta S, Iorio A, Peirone C, Nenci GG. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Thrombosis & Haemostasis 1996;75 (3):395-400. [MEDLINE: 2656].
53. Betteridge 1999 Betteridge DJ. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group. International Journal of Clinical Practice 1999;53(4):243- 50.
54. Blann 2001 Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GY. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. American Journal of Cardiology 2001;88(1):A7-8, 89-92. [MEDLINE: 5047].
55. Bonanno 1985 Bonanno G, Bonaccorso R, Dell'Ali O, Salanitri G. Sulodexide in the treatment of atherosclerosis: A controlled clinical trial. Acta Therapeutica 1985;11(1):87-98.
56. Broome 1967 Broome A, Cederlund J, Eklof B. The effect of nicotinic acid on muscle blood flow in intermittent claudication measured with xenon-133 clearance method. Scandinavian Journal of Clinical and Laboratory Investigation Supplement 1967;99:233-40.
57. Brown 1998 Brown AS, Bakker-Arkema RG, Yellen L, Henley RW Jr, Guthrie R, Campbell CF, et al.Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Journal of the American College of Cardiology 1998;32(3):665-72.
58. Calabro 1985 Calabro A, Rossi A, Baiocchi MR, Coscetti G, Fellin R, Crepaldi G. Effect of sulodexide on hemorheological parameters in a group of patients with peripheral arteriosclerotic vascular disease [Effecto del sulodexide su alcuni parametri emoreologici in un gruppo di pazienti con vasculopatia arteriosclerotica periferica]. Ricerca in Clinica e in Laboratorio 1985;15(Suppl 1):455-63.
59. Castano 2004 Castano G, Mas R, Gamez R, Fernandez L, Illnait J. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55(4):361-71.
60. Castelluccio 1991 Castelluccio A, Bologna E. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Current Medical Research & Opinion 1991;12(5):325-31.
61. Catania 1992 Catania G, Salanitri T. Pharmacological treatment of intermittent claudication: double blind controlled study of Sulodexide vs placebo. European Review for Medical and Pharmacological Sciences 1992;14 (3):149-57.
62. Ciuffetti 1989 Ciuffetti G, Mercuri M, Susta A, Lupattelli G, Pasqualini L, Lombardini R, et al.Effects of 3-glucosaminoglycan sulfate on hemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: A preliminary double-blind crossover study. Angiology 1989; 40(4):255-9.
63. CLAS Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, et al.Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83(2):438-47.
64. Blankenhorn DH, Brooks SH. Angiographic trials of lipid-lowering therapy. Arteriosclerosis 1981;1(4):242-9.
65. *Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods and baseline results. Controlled Clinical Trials 1987; 8(4):356-87.
66. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257(23):3233-40.
67. Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, et al.Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Arteriosclerosis & Thrombosis 1992;12(3):348-56.
68. Coffman 1983 Coffman JD, Rasmussen HM. The peripheral circulation and treatment of hyperlipoproteinemias. Atherosclerosis 1983;46(1):147-59.
69. Crepaldi 1986 Crepaldi G, Fellin R, Calabro A, Baiocchi MR, Rossi A, Lenzi S, et al.Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Monographs on Atherosclerosis 1986;14:215-21.
70. Crepaldi 1990 Crepaldi G, Fellin R, Calabro A, Rossi A, Ventura A, Mannarino E, et al.Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosclerosis 1990;81(3):233-43.
71. Davis 1975 Davis E, Rozov H. Xanthinol nicotinate in peripheral vascular disease. Practitioner 1975;215(1290):793-8.
72. Fischer 1980 Fischer M, Alexander K, Delbrueck A, Rahlfs V. Clofibrate-induced lowering of plasma fibrinogen and calf blood flow in patients with arterial occlusive disease [Clofibrat-induzierte plasmafibrinogensenkung und periphere durchblutung bei arterieller verschlusskrankheit]. Herz Kleislauf 1980;12(10):431-4.
73. Gallino 2004 Gallino A, Do DD, Alerci M, Baumgartner I, Cozzi L, Segatto JM, et al.Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy: Official Journal of the International Society of Endovascular Specialists 2004;11(6):595-604. [MEDLINE: 6393].
74. Giansante 1990 Giansante C, Calabrese S, Fisicaro M, Fiotti N, Mitri E. Treatment of intermittent claudication with antiplatelet agents. Journal of International Medical Research 1990;18(5):400-7. [MEDLINE: 43].
75. Head 1986 Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner 1986;230(1411):49-54.
76. Heller 1989 Heller RF, Elliott H, Bray AE, Alabaster M. Reducing blood cholesterol levels in patients with peripheral vascular disease: dietitian or diet fact sheet?. Medical Journal of Australia 1989;151(10): 566-8.
77. Hentzer 1967 Hentzer E. Treatment of peripheral arterial insufficiency with inositoli nicotinas (Hexanicit). Scandinavian Journal of Clinical and Laboratory Investigation Supplement 1967;99:226-32.
78. Hutchinson 1983 Hutchinson K, Oberle K, Crockford P, Grace M, Whyte L, Gee M, et al.Effects of dietary manipulation on vascular status of patients with peripheral vascular disease. JAMA 1983;249(24):3326- 30.
79. Ito 2001 Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, Orimo H. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). Journal of Atherosclerosis & Thrombosis 2001;8(2):33-44. [MEDLINE: 6917].
80. Kiff 1988 Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. British Journal of Clinical Practice 1988;42(4):141-5.
81. Kirk 1999 Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJ. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vascular Medicine 1999;4(1):23-6.
82. Kissin 1951 Kissin M, Stein JJ, Adleman RJ. The effect of drugs used in the treatment of intermittent claudication on the exercise tolerance of individuals with obliterating arteriosclerosis. Angiology 1951;2(3): 217-24.
83. Larsen 1969 Larsen OA, Lassen NA. Medical treatment of occlusive arterial disease of the legs. Walking exercise and medically induced hypertension. Angiologica 1969;6(5):288-301.
84. Leng 1998b Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD, Skinner ER, et al.Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clinical Nutrition 1998;17(6):265-71.
85. Lunetta 1992 Lunetta M, Salanitri T. Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. Journal of International Medical Research 1992;20(1):45-53.
86. Marzola 1985 Marzola M, Donati D, Indelli M, Malacarne P. Sulodexide in the treatment of vasculopathic hyperlipidaemic patients [Il sulodexide nel trattamento del vasculopatico iperlipidemico: studio in doppio cieco]. European Review for Medical & Pharmacological Sciences 1985; 7(2):273-9.
87. Maxwell 2000 Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vascular Medicine 2000;5(1):11-9.
88. Mori 1992 Mori TA, Vandongen R, Mahanian F, Douglas A. Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. Metabolism: Clinical & Experimental 1992;41(10):1059-1067. [MEDLINE: 3680].
89. O'Hara 1988 O'Hara J. A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication. Journal of International Medical Research 1985;13(6):322-7.
90. *O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. British Journal of Clinical Practice 1988;42(9):377-83.
91. Oxford Cholesterol Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al.Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. European Heart Journal 1994;15(2):255-69.
92. *Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, et al.Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. European Heart Journal 1997;18(2):235-41. [MEDLINE: 5024].
93. Palmieri 1982 Palmieri G, Perego M, Nazzari M, Casalini F. Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinaemia. Clinica Terapeutica 1982;101(6):603-14.
94. Palmieri 1987 Palmieri G, Ambrosi G, Cantoni S, Agrati AM, Palazzini E. Clinical evaluation of a native low molecular weight heparin in the management of symptomatic peripheral vasculopathy in the elderly. Current Therapeutic Research, clinical & Experimental 1987;41(6):998- 1009.
95. Perego 1981 Perego M, Nazzari M, Palmieri G. Parenterally administered glycuronil-glycosamine in atherosclerotic hyperlipidemic patients. Giornale della Arteriosclerosi 1981;6(3):289-298.
96. Pisano 1986 Pisano L, Moronesi F, Falco F, Stipa E, Fabbiani N, Dolfi R, et al.The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic disease. Controlled study of hyperlipidemic and diabetic subjects. Thrombosis Research 1986;41(1):23-31.
97. Ramirez-Tortosa 1999 Ramirez-Tortosa C, Lopez-Pedrosa JM, Suarez A, Ros E, Mataix J, Gil A. Olive oil- and fish oil-enriched diets modify plasma lipids and susceptibility of LDL to oxidative modification in free-living male patients with peripheral vascular diseases: the Spanish Nutrition Study [see comments]. British Journal of Nutrition 1999;82(1):31-9.
98. Ramírez-Tortosa 1999 Ramírez-Tortosa MC, Suárez A, Gómez MC, Mir A, Ros E, Mataix J, et al.Effect of extra-virgin olive oil and fish-oil supplementation on plasma lipids and susceptibility of low-density lipoprotein to oxidative alteration in free-living spanish male patients with peripheral vascular disease. Clinical Nutrition 1999;18(3):167-74. [MEDLINE: 6751].
99. Saunders 2000 Saunders E, Ferdinand K, Yellen LG, Tonkon MJ, Krug-Gourley S, Poland, M. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia. Journal of the National Medical Association 2000;92(7):319-326. [MEDLINE: 6197].
100. Schumer 1963 Schumer W, Battung VR, Foa PP. A clinical evaluation of diethanolamine salt of p-tolylmethylcarbinol camporic acid (Gallogen) in arteriosclerosis obliterans. Angiology 1963;14:381-2.
101. Shustov 1997 Shustov SB. Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Current Medical Research & Opinion 1997;13(10):573- 82.
102. Smith 1981 Smith RS, Warren DJ. Effect of nicotinic acid and dipyridamole on tissue blood flow in peripheral vascular disease. Pharmatherapeutica 1981;2(9):597-600.
103. Smith 1999 Smith DG, Leslie SJ, Szucs TD, McBride S, Campbell LM, Calvo C, et al.Cost of treating to a modified european atherosclerosis society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clinical Drug Investigation 1999;17(3):185-93.
104. Tyson 1979 Tyson VC. Treatment of intermittent claudication. Practitioner 1979; 223(1333):121-6.
105. Borreani 1993 Borreani B, Brizio L, Cianfanelli G, Colotto P, Pastorelli M, Zepponi E. Activity evaluation of sulodexide in chronic peripheral scleroatheromatous arteriopathy. Gazzetta Medica Italiana 1993;152(1-2):21-24.
106. Degni 1973 Degni M, Cilurzo O. Treatment of obstructive atherosclerosis of the lower extremities with the ER-113V. Revista Brasileira Cardiovascular 1973;9(2):83-98.
107. Di Stefano 1984 Di Stefano F, Patane S, Vinci M. Medical treatment of atherosclerosis: Controlled clinical trial with new glycosaminoglycan: Sulodexide. European Review for Medical & Pharmacological Sciences 1984;6(3): 525-532.
108. Mayer 2001 Mayer O, Hromadka M. Statins in the treatment of patients with arterial occlusive disease of the lower extremities. [Czech]. Vnitrni Lekarstvi 2001;47(10):664-9.
109. BNF BNF 53. Section 2.12 .lipid regulating drugs. http://www.bnf.org/bnf/ (accessed 27 July 2007).
110. Cochrane Handbook Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
111. Dormandy 1999 Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Seminars in Vascular Surgery 1999;12(2):123-37.
112. Duffield 1982 Duffield RG, Miller NE, Jamieson CW, Lewis B. A controlled trial of plasma lipid reduction in peripheral atherosclerosis - an interim report. British Journal of Surgery 1982;69(Suppl):S3-S5.
113. Duffield 1983 Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983;2(8351):639-42.
114. Dumville 2004 Dumville JC, Lee AJ, Smith FB, Fowkes FGR. The health related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. British Journal of General Practice 2004;54508:826-31.
115. Fowkes 1988 Fowkes FGR. Epidemiology of atherosclerotic disease in the lower limbs. European Journal of Vascular and Endovascular Surgery 1988;2 (3):283-91.
116. Fowkes 1991 Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1919;20(2):384-91.
117. Heald 2006 Heald CL, Fowkes FGR, Murray G, Price JF on behalf of the International ABI Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis 2006;189(1):61-9.
118. Lewis 1985 Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Medica Scandinavica Supplementum 1985;701:53-57.
119. LIPID Study Group Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long term intervention with pravastatin in ischaemic disease (LIPID) study group. New England Journal of Medicine 1998;339(19):1349-57.
120. Sacks 1996 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 1996;335(14):1001-9.
121. SSS Study Group 1994 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344: 1383-9.
122. Leng 1996 Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 1996, Issue 3.
123. Leng 1997 Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 1997, Issue 4.
124. Leng 1998 Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 1998, Issue 4.